NCT07359014

Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma

A Multicenter Clinical Study of Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 25 (estimated)
• Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study aims to investigate the efficacy and safety of CD19/BCMA CAR-T cells in treating relapsed/refractory multiple myeloma.

Detailed description

B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor T-cell (CAR-T) therapy is currently a crucial treatment for relapsed/refractory multiple myeloma, yet approximately half of patients still experience relapse with limited subsequent treatment options. Recent studies suggest that dual-target CAR-T may offer new hope for relapsed/refractory multiple myeloma. Preliminary studies in this project demonstrate that the independently designed CD19/BCMA CAR-T exhibits potent anti-myeloma activity both in vitro and in tumor-bearing animal models, positioning it as a potential therapeutic strategy for relapsed/refractory multiple myeloma. Therefore, this study aims to investigate the efficacy and safety of CD19/BCMA CAR-T cells in treating relapsed/refractory multiple myeloma in humans, with the goal of providing novel therapeutic approaches for this disease.

Conditions

• Relapse Multiple Myeloma

Interventions

Type	Name	Description
OTHER	Dual CD19/BCMA CAR-T	Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy

Timeline

• Start date: 2025-11-01
• Primary completion: 2027-10-31
• Completion: 2030-10-31
• First posted: 2026-01-22
• Last updated: 2026-01-22

Locations

1 site across 1 country: China